Spots Global Cancer Trial Database for Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer

Official Title: Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer

Study ID: NCT04021069

Conditions

Breast Cancer

Invasive Ductal Breast Carcinoma

Invasive Lobular Breast Carcinoma

Interventions

Radiomic, pathomic, and clinical markers

Study Description

Brief Summary: This study examines retrospective clinical data on patients diagnosed with breast cancer and monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence, distant metastasis, and disease-free survival. The hypothesis of this study is that breast cancer patients who achieve a pathological complete response (pCR) to neoadjuvant chemotherapy demonstrate distinct clinicopathomic biomarker signatures.

Detailed Description: The specific aims of the study are to (1) to identify clinicopathomic biomarkers from pre-treatment core biopsies that are predictive of response to neoadjuvant chemotherapy, (2) determine patterns of metastasis from primary breast cancer to other distant sites, (3) determine the rates of local recurrence in breast cancer patients, and (4) to determine if there are significant radiomic, pathomic, and clinical markers for recurrence and distant metastasis.